E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models - PubMed (original) (raw)
Comparative Study
. 2003 Nov;21(11):1328-35.
doi: 10.1038/nbt887. Epub 2003 Oct 12.
Affiliations
- PMID: 14555956
- DOI: 10.1038/nbt887
Comparative Study
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
Yaohe Wang et al. Nat Biotechnol. 2003 Nov.
Abstract
Oncolytic replication-selective adenoviruses constitute a rapidly growing therapeutic platform for cancer. However, the role of the host immune response and the E3 immunoregulatory genes of the human adenovirus were unknown until now. We identified four mouse carcinoma lines of variable permissivity for adenoviral gene expression, cytopathic effects and/or burst size. To determine E3 gene effects in immunocompetent tumor-bearing hosts, we injected tumors with one of three adenoviruses: Ad5 (E3 wild type), dl309 (del. E3 10.4/14.5, 14.7 kDa) or dl704 (del. E3 gp19 kDa). Compared with Ad5 and dl704, dl309 was cleared much more rapidly and/or its activity was lower in all four models. Intratumoral injection with dl309 resulted in markedly greater macrophage infiltration and expression of both tumor necrosis factor and interferon-gamma. Adenovirus replication, CD8(+) lymphocyte infiltration and efficacy were similar upon intratumoral injection with either dl704 or Ad5. E3-dependent differences were not evident in athymic mice. These findings have important implications for the design of oncolytic adenoviruses and may explain the rapid clearance of E3-10.4/14.5,14.7-deleted adenoviruses in patients.
Similar articles
- Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL. Zhu M, et al. J Virol. 2005 May;79(9):5455-65. doi: 10.1128/JVI.79.9.5455-5465.2005. J Virol. 2005. PMID: 15827160 Free PMC article. - Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
Bortolanza S, Bunuales M, Alzuguren P, Lamas O, Aldabe R, Prieto J, Hernandez-Alcoceba R. Bortolanza S, et al. Cancer Gene Ther. 2009 Sep;16(9):703-12. doi: 10.1038/cgt.2009.12. Epub 2009 Feb 20. Cancer Gene Ther. 2009. PMID: 19229289 - Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D. Liu TC, et al. Gene Ther. 2005 Sep;12(17):1333-46. doi: 10.1038/sj.gt.3302555. Gene Ther. 2005. PMID: 15920462 - Adenovirus immunoregulatory genes and their cellular targets.
Horwitz MS. Horwitz MS. Virology. 2001 Jan 5;279(1):1-8. doi: 10.1006/viro.2000.0738. Virology. 2001. PMID: 11145883 Review. No abstract available. - Mechanisms of E3 modulation of immune and inflammatory responses.
Fessler SP, Delgado-Lopez F, Horwitz MS. Fessler SP, et al. Curr Top Microbiol Immunol. 2004;273:113-35. doi: 10.1007/978-3-662-05599-1_4. Curr Top Microbiol Immunol. 2004. PMID: 14674600 Review.
Cited by
- E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.
Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, Lemoine NR, Halldén G. Cheong SC, et al. Cancer Gene Ther. 2008 Jan;15(1):40-50. doi: 10.1038/sj.cgt.7701099. Epub 2007 Nov 23. Cancer Gene Ther. 2008. PMID: 18034197 Free PMC article. - Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses.
Green-Tripp G, Nattress C, Halldén G. Green-Tripp G, et al. Front Mol Biosci. 2022 Jun 24;9:901392. doi: 10.3389/fmolb.2022.901392. eCollection 2022. Front Mol Biosci. 2022. PMID: 35813830 Free PMC article. Review. - Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G. Miranda E, et al. PLoS One. 2012;7(10):e46617. doi: 10.1371/journal.pone.0046617. Epub 2012 Oct 3. PLoS One. 2012. PMID: 23056370 Free PMC article. - Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.
Yang K, Feng S, Luo Z. Yang K, et al. Biomedicines. 2022 Dec 15;10(12):3262. doi: 10.3390/biomedicines10123262. Biomedicines. 2022. PMID: 36552019 Free PMC article. Review. - Ixovex-1, a novel oncolytic E1B-mutated adenovirus.
Anwar M, Arendt ML, Ramachandran M, Carlsson A, Essand M, Akusjärvi G, Alusi G, Öberg D. Anwar M, et al. Cancer Gene Ther. 2022 Nov;29(11):1628-1635. doi: 10.1038/s41417-022-00480-3. Epub 2022 May 20. Cancer Gene Ther. 2022. PMID: 35596069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials